HBIO vs. OPRX, APPS, QUIK, ASUR, CANG, III, OOMA, KLTR, TRVG, and INOD
Should you be buying Harvard Bioscience stock or one of its competitors? The main competitors of Harvard Bioscience include OptimizeRx (OPRX), Digital Turbine (APPS), QuickLogic (QUIK), Asure Software (ASUR), Cango (CANG), Information Services Group (III), Ooma (OOMA), Kaltura (KLTR), trivago (TRVG), and Innodata (INOD). These companies are all part of the "computer and technology" sector.
OptimizeRx (NASDAQ:OPRX) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap computer and technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.
Harvard Bioscience has higher revenue and earnings than OptimizeRx. Harvard Bioscience is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.
Harvard Bioscience has a net margin of -3.04% compared to Harvard Bioscience's net margin of -24.56%. OptimizeRx's return on equity of 2.75% beat Harvard Bioscience's return on equity.
Harvard Bioscience received 226 more outperform votes than OptimizeRx when rated by MarketBeat users. Likewise, 72.16% of users gave Harvard Bioscience an outperform vote while only 62.83% of users gave OptimizeRx an outperform vote.
OptimizeRx currently has a consensus price target of $15.86, indicating a potential upside of 77.37%. Harvard Bioscience has a consensus price target of $7.00, indicating a potential upside of 88.17%. Given OptimizeRx's higher probable upside, analysts clearly believe Harvard Bioscience is more favorable than OptimizeRx.
76.5% of OptimizeRx shares are owned by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are owned by institutional investors. 4.4% of OptimizeRx shares are owned by company insiders. Comparatively, 9.0% of Harvard Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
OptimizeRx has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, Harvard Bioscience has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.
In the previous week, OptimizeRx had 2 more articles in the media than Harvard Bioscience. MarketBeat recorded 7 mentions for OptimizeRx and 5 mentions for Harvard Bioscience. OptimizeRx's average media sentiment score of 0.31 beat Harvard Bioscience's score of -0.18 indicating that Harvard Bioscience is being referred to more favorably in the news media.
Summary
Harvard Bioscience beats OptimizeRx on 13 of the 17 factors compared between the two stocks.
Get Harvard Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for HBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Harvard Bioscience Competitors List
Related Companies and Tools
